Pharmacologic agents in complementary medicine in prostatic disease

Drugs of Today

Volumn 37, Issue 6, 2001, Pages 427-433

  Thompson, I M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AZUPROSTAT; CERNITIN; ISOFLAVAN DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYGEUM AFRICANUM EXTRACT; SELENIUM; SITOSTEROL; UNCLASSIFIED DRUG;

ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER PREVENTION; FAT INTAKE; HUMAN; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SABAL; SOYBEAN; VITAMIN SUPPLEMENTATION;

EID: 0034899021     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2001.37.6.627962     Document Type: Review

References (51)

1. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey
2. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: An epidemiological analysis
3. Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice
4. Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-Year follow-up of the prospective Basel study
5. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers
6. Biochemical studies of a selenium-deficient population in China: Measurement of selenium, glutathione peroxidase and other oxidant defense indices in blood
7. Selenium in agricultural drainage: Essential nutrient or toxic threat?
8. Possible protective effect of selenium against human cancer
9. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer
10. Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial
11. Genistein, daidzein and their β-glycoside conjugates: Antitumor isoflavones in soybean foods from American and Asian diets
12. Soy intake and cancer risk: A review of the in vitro and in vivo data
13. Plasma concentrations of phyto-estrogens in Japanese men
14. Genistein, a specific inhibitor of tyrosine-specific protein kinases
15. Genistein, a dietary-derived inhibitor of in vitro angiogenesis
16. Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines
17. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP
18. Cohort study of diet, lifestyle, and prostate cancer in Adventist men
19. Animal fat consumption and prostate cancer: A prospective study in Hawaii
20. A prospective study of dietary fat and risk of prostate cancer
21. Net energy effects of dietary fat on chemically induced mammary carcinogenesis in F344 rats
22. The early in utero oestrogen and testosterone environment of blacks and whites: Potential effects on male offspring
23. Effect of a vegetarian diet and dexamethasone on plasma prolactin, testosterone and dehydroepiandrosterone in men and women
24. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2
25. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3
26. Lovastatin-induced apoptosis in prostate stromal cells
27. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer
28. Estrogenic activity of natural and synthetic estrogens in human breast cancer cells in culture
29. pS2 expression induced by American ginseng in MCF-7 breast cancer cells
30. PCSPES: A unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo
31. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer
32. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
33. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues
34. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate
35. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: Effects on urodynamic parameters and voiding symptoms
36. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia
37. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review
38. Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5α-reductase activity in human benign prostatic hyperplasia
39. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients
40. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients
41. Lack of effects of a lyposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone
42. Effect of Pygeum africanum extract on A23187-stimulated production of lipoxygenase metabolites from human polymorphonuclear cells
43. Effects of Tadenan pretreatment on bladder physiology and biochemistry following partial outlet obstruction
44. Protective effect of Tadenan on bladder function secondary to partial outlet obstruction
45. Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts
46. Efficacy of Pygeum africanum extract in the treatment of micturitional disorders due to benign prostatic hyperplasia. Evaluation of objective and subjective parameters. A multicenter, randomized, double-blind trial
47. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer
48. Clinical evaluation of long-term treatment using cernitin pollen extract in patients with benign prostatic hyperplasia
49. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia
50. Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia
51. A multicentric, placebo-controlled, double-blind clinical trial of β-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia